Progyny (PGNY) Cash & Equivalents (2018 - 2026)

Progyny (PGNY) has 9 years of Cash & Equivalents data on file, last reported at $131.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 20.48% year-over-year to $131.6 million in Q1 2026; TTM through Mar 2026 was $131.6 million, a 20.48% increase from a year earlier, with the FY2025 full-year figure at $112.2 million, down 30.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $131.6 million, up from $112.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PGNY reached as high as $170.6 million in Q2 2023 and fell as low as $38.8 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $114.7 million across 5 years, with a median of $115.0 million in 2024.
• Across the five-year window, Cash & Equivalents jumped 300.09% in 2023 and slumped 44.33% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $120.1 million in 2022, then retreated by 18.97% to $97.3 million in 2023, then soared by 66.82% to $162.3 million in 2024, then slumped by 30.85% to $112.2 million in 2025, then gained by 17.26% to $131.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $131.6 million in Q1 2026, $112.2 million in Q4 2025, and $134.0 million in Q3 2025.